Information about Primary Pulmonary Hypertension and other forms of Severe Pulmonary Hypertension
PPH NEWS is an education-based resource site that provides information on the health issues surrounding Primary Pulmonary Hypertension (PPH), including what it is, the symptoms, diagnoses, and treatment options.
This website also provides resource to learn more about your legal rights and remedies if you or someone you know has developed PPH due to the use of diet drugs such as Fen Phen.
Primary Pulmonary Hypertension (PPH), also called Pulmonary Arterial Hypertension, is a rare disorder that leads to high blood pressure in the lungs. The blood vessels constrict, causing high pressure in the pulmonary artery, which connects the heart to the lungs, to rise. This chokes off the flow of blood between the heart and lungs, causing dizziness exhaustion, fainting and finally heart failure. PPH is diagnosed when all types of Secondary Pulmonary Hypertension (SPH) are excluded by the doctor. PPH is linked to use of the diet drug Fen Phen. There are no known cures for PPH, but treatment for the disease is improving.
On September 15, 1997, under pressure from the FDA, American Home Products Corporation withdrew from the market its diet drugs Pondimin (fenfluramine) and Redux (dexfenfluramine). Fen Phen, a combination of Pondimin and a mild stimulant called phentermine, was widely prescribed for weight loss. In 1996 alone, there were 18 million prescriptions written for Fen Phen in the United States. The FDA request for withdrawal of the diet drugs came after the Mayo Clinic in Minnesota released research showing 24 cases of rare heart valve disease in women who took Fen Phen.
If you used Fen Phen and have been diagnosed with PPH, you should contact us immediately to learn about your legal rights.
According to a study released February 8, 2006, women who take Paxil, Zoloft, and other antidepressants late in their pregnancies are at an increased risk of delivering babies with a serious lung condition called persistent or primary pulmonary hypertension.
While this condition is commonly called primary pulmonary hypertension (PPH) in adults, the condition is given the name persistent pulmonary hypertension of the newborn (PPHN) when it affects infants. The term "persistent" is applied because it is common for infants to be born with high pressure in the lungs. Typically, this high pressure decreases in the first hours and days of life. Infants whose circulation systems are unable to adapt to breathing outside the womb have what is called persistent pulmonary hypertension of the newborn.
Patients suffering from Primary Pulmonary Hypertension (PPH) caused by Fen-Phen, Pondimin or Redux are not included in the Nationwide Class Action Settlement Agreement with American Home Products. PPH patients must file independent lawsuits to make legal claims. Please contact us to speak with a PPH Lawyer for lawsuit information.
Common side effects of PPH, irreversible pulmonary hypertension or other severe pulmonary hypertensions include deaths, chest pain, heart murmurs, fainting, shortness of breath, weakness, fatigue, tiredness
Use of Flolan, Tracleer or Remodulin indicate very severe pulmonary hypertension. These drugs are only prescribed in the most serious cases, and their use is indicative of the severity of the condition but never the cause of the condition. If you or a family member are on Flolan, Tracleer, or Remodulin, the medication should be continued as instructed by your physician.
Contact us if you are on one of these drugs and want us to review your prior medications to determine if they might be one of the causes of primary pulmonary hypertension, irreversible pulmonary hypertension or other severe pulmonary hypertension.